|
|
|
Key GU Oncology Data to Watch at ASCO 2026
|
|
Rana McKay, MD
|
| Rana McKay previews five ASCO 2026 GU oncology trials. PROTEUS, a plenary presentation, tests perioperative apalutamide plus ADT versus placebo plus ADT before radical prostatectomy in high-risk prostate cancer, with co-primary endpoints of pathologic complete response and metastasis-free survival.
|
|
|
|
|
|
|
|
|
|
|
|
|
Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
|
|
PRESS RELEASE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights from the Upcoming 2026 American Society of Clinical Oncology Annual Meeting
|
|
|
|
|
|
| Kidney and Bladder Cancer - Oral Abstracts - 14:45-17:45
|
|
|
|
|
A Phase 2 Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with RCC with Bone Metastases: RADICAL (Alliance A031801)
Presented By: Rana McKay, MD
|
|
|
|
|
ctDNA Analysis in Participants with RCC Treated with Adjuvant Pembrolizumab in the KEYNOTE-564 Trial
Presented By: Toni Choueiri, MD
|
|
|
|
|
Discussant - Is the Best yet to Come in Kidney Cancer?
Presented By: Martin Voss, MD
|
|
|
|
|
Enfortumab Vedotin + Pembrolizumab vs Chemotherapy for Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 3.5 Year Follow-up and Response Analyses from the Phase 3 EV-302 Study
Presented By: Thomas Powles, MD, MBBS, MRCP
|
|
|
|
|
Initial Results from NEXUS-01, a Phase 1 Study of LY4052031, an ADC Targeting Nectin-4, in Participants with Advanced or Metastatic Urothelial Carcinoma
Presented By: Gopa Iyer, MD
|
|
|
|
|
|
|
| New Approaches to Curing Bladder and Kidney Cancer - 08:00-09:30
|
|
|
|
|
New Approaches to Curing Bladder and Kidney Cancers: Where Do We Stand Today?
Presented By: Srikala Sridhar, MD, MSc, FRCPC
Durvalumab Monotherapy Versus Active Monitoring for Resected Primary RCC in RAMPART: An International, Phase 3, Randomized Controlled Trial
Presented By: James Larkin, PhD, FRCP, FMedSci
Feasibility and Safety Results from RAD-IO: A Multi-Stage Trial of Durvalumab with Chemoradiotherapy with 5-FU and Mitomycin C in Pts with MIBC
Presented By: Nicholas James, PhD, FRCP, MBBS
|
|
|
|
|
|
|
|
|
|
| Prostate, Testicular, and Penile Cancer - Oral Abstracts- 15:00-18:00
|
|
|
|
|
Assessment of the Ability of Decipher Prostate Genomic Classifier >0.85 to Identify Patients Who Benefit from Adding Docetaxel to ADT + Enzalutamide: Level 1B Evidence from the ENZAMET Study
Presented By: Christopher Sweeney, MBBS
|
|
|
|
|
First Interim Analysis of SWOG S1823: Operating Characteristics of miR371 in Predicting Active Germ Cell Malignancy in Patients with Early-Stage Testicular Cancer
Presented By: Lucia Nappi, MD, PhD
|
|
|
|
|
A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to Androgen Receptor Pathway Inhibitor in mHSPC (A-DREAM / Alliance A032101)
Presented By: Atish Choudhury, MD, PhD
|
|
|
|
|
Cognitive Effects of Darolutamide vs Enzalutamide: Results of ARACOG (AFT-47), a Randomized Clinical Trial from the Alliance for Clinical Trials in Oncology
Presented By: Alicia Morgans, MD, MPH
|
|
|
|
|
Discussant - Minimizing Toxicity and Maximizing Patient Benefit in Prostate Cancer
Presented By: Catherine Marshall, MD, MPH
|
|
|
|
|
TALAPRO-3: Talazoparib + Enzalutamide Compared with Placebo + Enzalutamide for the Treatment of Patients with mCSPC Harboring HRR Gene Alterations
Presented By: Neeraj Agarwal, MD, FASCO
|
|
|
|
|
|
|
| Kidney and Bladder Cancer - Posters - 09:00-12:00
|
|
|
|
|
| Prostate, Testicular, and Penile Cancer - Posters - 09:00-12:00
|
|
|
|
|
| Plenary Session - 13:00 - 16:00
|
|
|
|
|
Perioperative (Neoadjuvant and Adjuvant) Apalutamide + ADT vs Placebo + ADT with Radical Prostatectomy in High-Risk Localized or Locally Advanced Prostate Cancer: Final Analysis of the PROTEUS Phase 3 Study
Presented By: Mary-Ellen Taplin, MD
|
|
|
|
|
PROTEUS - Discussant
Presented By: Declan Murphy, MB, BCH, BaO, FRACS, FRCS Urol
|
|
|
|
|
| Prostate, Testicular, and Penile Cancer - Rapid Oral Abstracts - 16:30-18:00
|
|
|
|
|
Early Results of COMPPARE, a Prospective Comparison of Outcomes with Proton and Photon Radiation in Prostate Cancer
Presented By: Nancy Mendenhall, MD, FACR, FASTRO
|
|
|
|
|
|
|
| Kidney and Bladder Cancer - Rapid Oral Abstracts - 08:00-09:30
|
|
|
|
|
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab Versus Avelumab After 1L PBC in Patients with la/mUC (Alliance A032001)
Presented By: Shilpa Gupta, MD
Durvalumab in Combination with BCG Induction and Maintenance Therapy for BCG-Naïve, High-Risk NMIBC: 5 Year Overall Survival Analysis and PROs from POTOMAC
Presented By: Maria De Santis, MD
Interim Analysis from Duravelo-2: Zelenectide Pevedotin + Pembrolizumab in Patients with Previously Untreated la/mUC
Presented By: Yohann Loriot, MD, PhD
|
|
|
|
|
|
|
|
|
|
Final Results of a Phase 2 Trial of Cabozantinib + Nivolumab in Patients with Non-Clear Cell RCC
Presented By: Darren Feldman, MD
|
|
|
|
|
| Optimizing Care for Patients with mCRPC - 11:30-12:45
|
|
|
|
|
First-Line Metastatic Castration-Resistant Prostate Cancer: One Size Doesn't Fit All
Presented By: Karim Fizazi, MD, PhD
|
|
|
|
|
How to Better Personalize Treatment with Lu-PSMA
Presented By: Louise Emmett, MBChB, FRACP, FAANMS, MD
|
|
|
|
|
| Radiation Re-Imagined: Radioligand Innovation in Prostate Cancer - 15:00-16:30
|
|
|
|
|
Safety and Dosimetry of 177Lu-Rosopatamab Tetraxetan plus SOC in Patients with mCRPC: Preliminary Results from Part 1 of Phase 3 ProstACT Global Study
Presented By: Pedro Barata, MD, MSc FACP
|
|
|
|
|
AcTION: Phase 1 Study of [225Ac]Ac-PSMA-617 in Men with mCRPC with or Without Prior [177Lu]Lu-PSMA Radioligand Therapy
Presented By: Louise Emmett, MBChB, FRACP, FAANMS, MD
|
|
|
|
|
